Insulet hopes to see 600,000 insulin pumps by end-2009
CHICAGO Insulin pump maker Insulet has a big goal for the end of next year.
The company hopes to increase production of its disposable insulin pump for diabetics, the OmniPod, to 600,000 by the end of 2009. Its main competitor, Medtronic, announced earlier this month that it plans to start selling a tubeless insulin patch within two years.
Insulet’s plan involves the OmniPod, an insulin pump smaller and easier to wear than other pumps. Most pumps have several feet of tubes that patients must hide under their clothing, but the OmniPod delivers insulin directly through a small tube.
Insulet said it plans to increase production by the end of this year to 200,000 pumps per month, enough to supply 12,000 patients.
Insulin pumps are used as replacements for the several injections diabetics must take by syringe or insulin pen every day. Most users of the pumps have Type 1 diabetes.
Study: pharmacist monitoring can help hypertension
SEATTLE An experiment by the Seattle-based Group Health Cooperative has found that Web-based monitoring by pharmacists can help control hypertension.
It found that 56 percent of patients assigned home blood pressure monitoring, Web site training and Web-based pharmacist care experienced increases in control of blood pressure. Those who received the blood pressure monitoring and Web site training only did not experience a significant increase.
The study involved 778 patients ages 25 to 75 in three groups with uncontrolled essential hypertension and Internet access between June 2005 and December 2007.
Results of the study appeared in Wednesday’s issue of the Journal of the American Medical Association.
Genzyme, Isis complete license agreement for cholesterol drug
CAMBRIDGE, Mass. Genzyme and Isis Pharmaceuticals announced Tuesday that they had finished a license and collaboration agreement for mipomersen, a drug candidate designed for patients with high cholesterol.
Under the agreement, Genzyme will pay Isis $175 million in licensing fees. Isis will contribute up to $175 million for development. After that, the two companies will share development costs. Isis may also receive up to $1.5 billion in commercial, development and regulatory milestone payments. Genzyme will have preferred access to future drugs that Isis develops for rare diseases and diseases affecting the central nervous system.
The companies will share profits for the drug, with Genzyme receiving 70 percent and Isis receiving 30 percent. They will split profits equally once revenues on mipomersen reach $2 billion. Genzyme will also be responsible for funding sales and marketing until revenues can cover them.
“Mipomersen is an innovative treatment that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current cholesterol-lowering therapies,” said Henri A. Termeer, Genzyme’s chairman and chief executive officer.